We propose to conduct a pilot study to confirm the efficacy of bumetanide as add-on treatment to reduce irritability and other behavioral symptoms typical in children and adolescents with TSC, with and without mental retardation.
ID
Bron
Verkorte titel
Aandoening
Tuberous Sclerosis Complex (TSC)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Aberrant Behavior Checklist (ABC) irritability subscale
Achtergrond van het onderzoek
Pilot open label study confirming the applicability and efficacy of bumetanide as add-on
treatment for behavioural problems and seizures in 2x10 patients with TSC and a history of
behavioural problems between 8 and 15 years of age. After the baseline screening, included
subjects receive bumetanide for 91 days, followed by a 28 days discontinuation phase, after which endpoint monitoring will be repeated to evaluate the persistence of treatment effect. Test battery assessment will take place at baseline, at the end of bumetanide treatment (Day 91) and after the discontinuation phase (Day 119). The primary endpoint of the study is the ABC-I subscale at Day 91. In addition, a number of cognitive and neurophysiological markers as well as measures of seizure control will be tested.
Doel van het onderzoek
We propose to conduct a pilot study to confirm the efficacy of bumetanide as add-on treatment to reduce irritability and other behavioral symptoms typical in children and adolescents with TSC, with and without mental retardation.
Onderzoeksopzet
• Pre-treatment and screening
o Screening for eligibility
o Baseline measurements
• Treatment (D0 to D91)
o Blood analysis at D4, D7, D14, D28, D56
o End of treatment outcome measurements D91
• Washout (D91 to D119)
o End of washout outcome measurements D119
Onderzoeksproduct en/of interventie
The investigational product will consist of bumetanide, which will be provided for 91 days as an add-on treatment, supplementary to the regular use of AEDs or other (allowed) co-medications. Dose reductions to manage side effects will be allowed at any time. Based upon the expected chance of frequent mild to moderate hypokalemia, all subjects will receive standard potassium supplementation during the 91 days of treatment. The treatment period will be followed by a wash-out period to evaluate
return of symptomatology and reversibility of treatment effect.
Publiek
D.M. van Andel
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
+31(0)88-7550776
D.M.vanandel@umcutrecht.nl
Wetenschappelijk
D.M. van Andel
Heidelberglaan 100
Utrecht 3584 CX
The Netherlands
+31(0)88-7550776
D.M.vanandel@umcutrecht.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
General inclusion criteria:
1. Males and females aged 8-15 years
2. Definite diagnosis of TSC: either meeting criteria for clinical definite TSC, or a mutation
identified in the TSC1 or TSC2 gene
3. History of behavioral problems
4. Written informed consent
Specific inclusion criteria Group 1:
- No intellectual disability (TIQ>70)
Specific inclusion criteria Group 2:
- Intellectual disability (TIQ≤70)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. Inability to comply with the protocol-specified procedures
2. Presence of a severe medical or genetic disorder other than related to TSC or epilepsy
3. Serious, unstable illnesses
4. Renal insufficiency, congenital or acquired renal disease with decreased concentration capacity and liver insufficiency interfering with excretion or metabolism of bumetanide
5. Behavioral treatment
6. Treatment with psychoactive medications, including antipsychotics, antidepressants,
anxiolytic drugs, psychostimulant drugs, except melatonin. If clinically feasible, then it is allowed to stop psychoactive medication to allow enrolment in the study after a 4 week washout
period of their psychoactive medication. Notably, an exception is treatment with AEDs,
which are allowed albeit on a stable regime in terms of types of AEDs and dosage from 2
months prior to the study to the end of the study
7. Treatment with NSAIDS, aminoglycosides, digitals, antihypertensive agents,
indomethacin, probenecid, acetazolamide, Lithium, other diuretics, drugs known to have a nephrotoxic potential
8. Documented history of hypersensitivity reaction to sulfonamide derivatives
9. Body weight < 30 kg
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL5962 |
NTR-old | NTR6328 |
CCMO | NL58183.041.16 |
OMON | NL-OMON45855 |